Prostate Cancer Risk by BRCA2 Genomic Regions.


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
10 2020
Historique:
received: 28 01 2020
accepted: 05 05 2020
pubmed: 14 6 2020
medline: 16 7 2021
entrez: 14 6 2020
Statut: ppublish

Résumé

A BRCA2 prostate cancer cluster region (PCCR) was recently proposed (c.7914 to 3') wherein pathogenic variants (PVs) are associated with higher prostate cancer (PCa) risk than PVs elsewhere in the BRCA2 gene. Using a prospective cohort study of 447 male BRCA2 PV carriers recruited in the UK and Ireland from 1998 to 2016, we estimated standardised incidence ratios (SIRs) compared with population incidences and assessed variation in risk by PV location. Carriers of PVs in the PCCR had a PCa SIR of 8.33 (95% confidence interval [CI] 4.46-15.6) and were at a higher risk of PCa than carriers of other BRCA2 PVs (SIR = 3.31, 95% CI 1.97-5.57; hazard ratio = 2.34, 95% CI 1.09-5.03). PCCR PV carriers had an estimated cumulative PCa risk of 44% (95% CI 23-72%) by the age of 75 yr and 78% (95% CI 54-94%) by the age of 85 yr. Our results corroborate the existence of a PCCR in BRCA2 in a prospective cohort. PATIENT SUMMARY: In this report, we investigated whether the risk of prostate cancer for men with a harmful mutation in the BRCA2 gene differs based on where in the gene the mutation is located. We found that men with mutations in one region of BRCA2 had a higher risk of prostate cancer than men with mutations elsewhere in the gene.

Identifiants

pubmed: 32532514
pii: S0302-2838(20)30345-6
doi: 10.1016/j.eururo.2020.05.005
pmc: PMC7532700
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

494-497

Subventions

Organisme : Cancer Research UK
ID : C12292/A20861
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C12292/A22820
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C5047/A8385
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Nat Genet. 1997 Jan;15(1):103-5
pubmed: 8988179
JAMA. 2015 Apr 7;313(13):1347-61
pubmed: 25849179
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Am J Hum Genet. 2001 Feb;68(2):410-9
pubmed: 11170890
Stat Med. 1991 Jul;10(7):1025-35
pubmed: 1652152
Eur Urol. 2020 Jan;77(1):24-35
pubmed: 31495749
Cancer Res. 2020 Feb 1;80(3):624-638
pubmed: 31723001
J Med Genet. 2005 Sep;42(9):711-9
pubmed: 16141007
Oncogene. 2006 Jan 12;25(2):323-8
pubmed: 16170354

Auteurs

Tommy Nyberg (T)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Electronic address: ten25@medschl.cam.ac.uk.

Debra Frost (D)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Daniel Barrowdale (D)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

D Gareth Evans (DG)

Manchester Regional Genetics Service, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.

Elizabeth Bancroft (E)

Oncogenetics Team, Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK.

Julian Adlard (J)

Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Munaza Ahmed (M)

North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Trust, London, UK.

Julian Barwell (J)

Leicestershire Clinical Genetics Service, University Hospitals of Leicester NHS Trust, Leicester, UK.

Angela F Brady (AF)

North West Thames Regional Genetics Service, London North West University Healthcare NHS Trust, London, UK.

Carole Brewer (C)

Peninsula Clinical Genetics Service, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

Jackie Cook (J)

North Trent Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK.

Rosemarie Davidson (R)

West of Scotland Regional Genetics Service, NHS Greater Glasgow and Clyde, Glasgow, UK.

Alan Donaldson (A)

South Western Regional Genetics Service, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.

Jacqueline Eason (J)

Nottingham Centre for Medical Genetics, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Helen Gregory (H)

North of Scotland Regional Genetics Service, NHS Grampian, Aberdeen, UK.

Alex Henderson (A)

Northern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

Louise Izatt (L)

South East Thames Regional Genetics Service, Guy's and St Thomas' NHS Foundation Trust, London, UK.

M John Kennedy (MJ)

St James's Hospital, Dublin, Republic of Ireland; National Centre for Medical Genetics, Dublin, Republic of Ireland.

Claire Miller (C)

Merseyside and Cheshire Clinical Genetics Service, Liverpool Women's NHS Foundation Trust, Liverpool, UK.

Patrick J Morrison (PJ)

Northern Ireland Regional Genetics Service, Belfast Health and Social Care Trust, Belfast, UK.

Alex Murray (A)

Medical Genetics Services for Wales, Abertawe Bro Morgannwg University Health Board, Swansea, UK.

Kai-Ren Ong (KR)

West Midlands Regional Genetics Service, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Mary Porteous (M)

South East of Scotland Regional Genetics Service, NHS Lothian, Edinburgh, UK.

Caroline Pottinger (C)

Medical Genetics Services for Wales, Betsi Cadwaladr University Health Board, Bodelwyddan, UK.

Mark T Rogers (MT)

All Wales Medical Genetics Service, NHS Wales, Cardiff, UK.

Lucy Side (L)

Wessex Clinical Genetics Service, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Katie Snape (K)

South West Thames Regional Genetics Service, St George's University Hospitals NHS Foundation Trust, London, UK.

Vishakha Tripathi (V)

South East Thames Regional Genetics Service, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Lisa Walker (L)

Oxford Regional Genetics Service, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Marc Tischkowitz (M)

Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.

Rosalind Eeles (R)

Oncogenetics Team, Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK.

Douglas F Easton (DF)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Antonis C Antoniou (AC)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH